ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
About the study
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
Documented diagnosis of AHP, per physician's determination
EXCLUSION CRITERIA
Exclusion Criteria:
Currently enrolled in a clinical trial for any investigational agent
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Acute Hepatic Porphyria
Age (in years)
12+
Participants needed
150
Est. Completion Date
Apr 30, 2027
Treatment type
Observational
Sponsor
Alnylam Pharmaceuticals
ClinicalTrials.gov identifier
NCT04883905
Study number
ALN-AS1-006
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?